Dr. Boerman is an experienced senior executive who previously held leadership positions with Catalent, DSM, Patheon, Consort Medical and Kiadis Pharma. In her last role as President of Catalent’s Cell, Gene and Protein Therapy Division she led, built and help grow a world class organization offering development and GMP manufacturing services for new modalities as cell and gene therapies. Dr. Boerman started her career with DSM in The Netherlands. She has a PhD in Biochemistry from the State University of New York at Buffalo in the United States.

“Dr. Boerman brings over 20 years of knowledge and expertise in the biopharmaceutical space, along with a proven track record of building, turning around and growing international companies to become leading, strong organizations,” said Nir Epstein, Executive Director and Vice Chairman of Prothya.

“I am excited to join Prothya and look forward to working with all team members and stakeholders to build a global leading company offering lifesaving plasma derived medicines to patients world-wide. I am also honored to work for all volunteer donors of blood plasma who enable making these essential medicines available for people in need,” said Dr. Boerman.

Media Contact

Questions can be send to info@prothya.com.

About Prothya Biosolutions

Prothya Biosolutions is committed to providing healthcare-oriented organizations worldwide with high-quality services and plasma-derived medicinal products. In doing so, we create value for our partners and contribute to sustaining the health of people who depend on essential plasma-derived medicines. In other words: Creating value, sustaining life. Prothya Biosolutions uses advanced methods to isolate proteins from blood plasma and turn them into life-saving medicines. Prothya produces plasma-derived medicinal products under its own brand for use in immunology and critical care, and we make our knowledge and infrastructure available to various partners.